Skip to main
TLX

TLX Stock Forecast & Price Target

TLX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Telix Pharmaceuticals is poised for significant growth due to its pipeline of potential radiopharmaceuticals and its successful partnership with Regeneron to develop and commercialize radiopharma therapies targeting multiple solid tumors. This collaboration not only provides Telix with upfront funding and potential milestones/royalties, but also validates the use of radiopharmaceuticals in oncology. With a sum-of-parts valuation and potential market value of $6.66B, Telix has a positive outlook with risks including negative clinical results, delays in advancing pipeline candidates, regulatory approvals, competition, and long-term dilution risk.

Bears say

Telix Pharmaceuticals is currently generating most of its revenue from US sales of Illuccix, a prostate cancer imaging agent, and has a pipeline of potential radiopharmaceuticals in development. However, the upcoming regulatory milestones for TLX's PSMA imaging portfolio, as well as the resubmission of its NDA for Pixclara in the US and MAA in Europe and BLA for Zircaix in 1H26, create potential for incremental growth in the future. These developments, coupled with Telix's low sales multiple compared to its peers, suggest a negative outlook for its stock.

TLX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Telix Pharmaceuticals Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Telix Pharmaceuticals Ltd (TLX) Forecast

Analysts have given TLX a Strong Buy based on their latest research and market trends.

According to 4 analysts, TLX has a Strong Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Telix Pharmaceuticals Ltd (TLX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.